Who Vaping Covid: What the Latest Data Shows
Public health agencies have studied whether vaping affects COVID-19 outcomes. The CDC notes that smoking and vaping can impair lung function, potentially increasing vulnerability to respiratory infections like COVID-19. Research published in peer-reviewed journals has linked vaping to higher rates of severe illness and hospitalization among infected individuals. The FDA continues to regulate vaping products and monitor health signals related to infectious diseases.
Surveys and hospitalization data show that younger adults and adolescents who vape may face elevated risks during COVID-19 surges. The NIH and other research bodies have funded studies examining biomarkers, immune response, and lung inflammation in vapers who contract COVID-19. These findings support existing warnings about noncombustible nicotine products and respiratory health, especially during pandemic waves. For an overview of federal vaping regulations, see the FDA's tobacco product page here.
Companies, Markets, and Regulatory Actions Related to Vaping
Major Vaping Companies and Compliance
Leading e-cigarette manufacturers have faced scrutiny during the pandemic over product marketing, supply chains, and public health messaging. The FDA has issued marketing denial orders and enforcement actions against unauthorized vaping products, citing concerns about youth access and health risks. Companies that submit premarket tobacco product applications must meet data standards on ingredients, toxicity, and public health impact.
Stock analysts and financial outlets have tracked how vaping stocks respond to regulatory news, COVID-19 research, and shifts in consumer behavior. Bloomberg and Reuters have reported on quarterly earnings, FDA timelines, and litigation involving major brands. Investors monitoring the sector look for updates on compliance, international sales, and harm-reduction claims tied to COVID-19-era health guidance. For details on SEC filings and company disclosures, see the SEC's EDGAR search page here.
Public Health Guidance and Ongoing Research
Health Agencies and Data Sources
The WHO and CDC have updated guidance on vaping during the pandemic, emphasizing that non-smokers should not start vaping and that smokers who quit can reduce respiratory risks. Studies from universities and health departments have examined COVID-19 test positivity, symptom severity, and recovery times among vapers compared with nonvapers.
Health departments continue to collect data on vaping prevalence, COVID-19 hospitalizations, and vaccination uptake. These datasets help policymakers design targeted campaigns and cessation programs. The NIH maintains a repository of COVID-19 research articles that include vaping status as a variable for analysis. For current CDC recommendations on vaping and respiratory health, see the CDC's smoking and tobacco use section here.